Added to YB: 2026-02-06
Pitch date: 2026-02-04
ABVX [bullish]
ABIVAX Société Anonyme
+15.06%
current return
Author Info
Company Info
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.
Market Cap
EUR 7.5B
Pitch Price
EUR 95.60
Price Target
N/A
Dividend
N/A
EV/EBITDA
-32.21
P/E
-21.62
EV/Sales
1.3K
Sector
Biotechnology
Category
special_situation
Special Situation: All Eyes on ABVX
ABVX: Non-biotech investor sees opportunity post-P3 obefazimod success (+600% July '25). Drug positioned as next best-in-class UC treatment, commercialization 2027. LLY/AZN buyout rumors circulating. Maintenance data Q2'26. De-risked asset limits downside, buyout upside or commercial fallback both viable.
Read full article (2 min)